September 9, 2021 -- Boehringer Ingelheim and Twist Bioscience have entered a research collaboration to discover therapeutic antibodies against multiple targets.
According to the agreement, Twist Biopharma, a division of Twist, will use its panel of synthetic antibody phage display libraries derived from human sequences to identify potential therapeutic antibody candidates. Twist and Boehringer will work together to validate and optimize any resulting new antibody candidates for use in multiple therapeutic areas.
Twist will receive an upfront payment for each program entry, and the company could potentially earn up to $710 million in success-based clinical, regulatory, and commercial milestone payments for the multiple target discovery programs.
Already have an account? Sign in Here
To access all ScienceBoard content create a free account now: